Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.
Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.
As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.
Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.
For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.
Sera Prognostics (NASDAQ: SERA) partners with Fors Marsh to introduce the PreTRM® Test as part of employee maternity benefits, effective January 1, 2023. This innovative blood-based test provides early risk assessments for spontaneous preterm births, identifying nearly 90% of at-risk pregnancies. Fors Marsh aims to enhance workforce health and cut maternity costs through this offering. Sera asserts that the PreTRM® Test's predictive capabilities contribute significantly to improving maternal and neonatal health outcomes.
Sera Prognostics Inc. (NASDAQ: SERA) published results from the ACCORDANT study, demonstrating the clinical utility and cost-effectiveness of its PreTRM® test. The study showed that enhanced care management for at-risk pregnant women could reduce neonatal and maternal hospital stays by 19% and 8.5%, respectively. Moreover, it predicted a 29% decrease in neonatal morbidity and mortality rates. These benefits were significant across diverse racial and ethnic groups. The findings highlight the potential of the PreTRM® test to address healthcare disparities in preterm birth, affecting over 10% of U.S. births annually.
Sera Prognostics Inc. (Nasdaq: SERA) reported third-quarter 2022 revenue of $87,000, up from $23,000 in Q3 2021. Total operating expenses increased to $11.3 million from $9.5 million year-over-year. R&D expenses rose to $4.2 million due to heightened laboratory and clinical study costs, while SG&A expenses slightly increased to $7.0 million. The net loss was $10.7 million, compared to $9.9 million in Q3 2021. The company holds approximately $111.2 million in cash and equivalents as of September 30, 2022.
Sera Prognostics (Nasdaq: SERA) will report its third quarter fiscal year 2022 financial results on November 9, 2022, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the financial results and operational highlights. Sera is focused on improving maternal and neonatal health through its precision medicine PreTRM® test, which predicts preterm birth risk. The company aims to enhance clinical decision-making for high-risk pregnancies, addressing a significant healthcare issue with estimated annual costs in the U.S. of $25 billion related to preterm birth.
Sera Prognostics, Inc. (NASDAQ: SERA) announces collaboration with Sonrava Health and Cerebrae to integrate its PreTRM® Test into Sonrava's employee maternity benefits. The PreTRM® Test, a clinically validated blood test, helps identify nearly 90% of pregnancies at risk for spontaneous preterm births, enabling proactive interventions. Through Cerebrae’s platform, value-based care strategies are evaluated, forecasting a positive ROI for Sonrava Health. This partnership aims to enhance maternal and neonatal health while promoting cost-effective healthcare solutions.
Sera Prognostics announced that its PreTRM® Test will be available to members of Banner – University Family Care. This test offers a unique, clinically validated method for assessing the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The partnership aims to enhance maternal and neonatal health while reducing healthcare costs. A prior economic analysis indicated that the PreTRM strategy could improve outcomes and lower treatment expenses compared to standard care. This collaboration reflects a shared commitment to innovative healthcare models.
Sera Prognostics Inc. (Nasdaq: SERA) reported its second quarter financial results for 2022, achieving a revenue of $78,000, up from $20,000 in Q2 2021. Operating expenses rose to $11.8 million, compared to $7.4 million in the previous year. The net loss for the quarter was $11.5 million, widening from $6.3 million a year ago. The company highlighted improved performance of the PreTRM test and contracts with new self-insured employer plans. As of June 30, 2022, cash and equivalents stood at approximately $121 million.
Sera Prognostics, focused on maternal and neonatal health, will release its second quarter fiscal year 2022 financial results on August 10, 2022, post-market. The conference call will start at 5:00 p.m. ET. Sera's PreTRM® Test helps predict preterm birth risks, addressing a significant health concern. The company aims to provide essential pregnancy biomarker information to healthcare providers to enhance patient outcomes and reduce healthcare costs. Additionally, it faces market risks that could impact its growth and revenue potential.
Sera Prognostics, Inc. (Nasdaq: SERA), a leader in maternal health diagnostics, will present at the 42nd Annual William Blair Growth Stock Conference on June 7, 2022, at 3:20 p.m. CT. CEO Gregory C. Critchfield will discuss the company's latest developments, including its innovative PreTRM® test, which predicts premature birth risk. The event will be available via live webcast on Sera's Investor website. Sera aims to improve healthcare outcomes for mothers and infants through precision medicine and has a significant pipeline focused on pregnancy-related complications.
Sera Prognostics, Inc. (NASDAQ: SERA) published data showing improved performance of its PreTRM® test for predicting spontaneous preterm birth. The study demonstrated an 88% sensitivity and 99% negative predictive value, indicating increased accuracy and reliability. The test can now be performed more conveniently during pregnancy, enhancing access for women at risk. These findings were published in the Journal of Clinical Medicine and align with updated ACOG gestational age guidelines, emphasizing Sera's commitment to improving maternal health.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is Sera Prognostics' main product?
Where is Sera Prognostics headquartered?
What is the mission of Sera Prognostics?
Who are some of the major investors in Sera Prognostics?
What recent financial milestone has Sera Prognostics achieved?
How does the PreTRM® Test work?
What are the benefits of the PreTRM® Test?
What strategic partnerships does Sera Prognostics have?
What are the company's future plans for expanding its product offerings?
What challenges does Sera Prognostics face?
